Evidence map›Paper›PMID 31657775›Full record

ArticleThe Lancet. Infectious diseases2019

Suboptimal dosing triggers artemisinin partner drug resistance.

Jigang Wang, Chengchao Xu, Fu Long Liao, Tingliang Jiang, Sanjeev Krishna, Youyou Tu

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in The Lancet. Infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Discovery and repurposing of artemisinin.Frontiers of medicine · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Jigang WangShenzhen People's Hospital, Shenzhen 518020, China; Artemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Chengchao XuShenzhen People's Hospital, Shenzhen 518020, China; Artemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Fu Long LiaoArtemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Tingliang JiangArtemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Sanjeev KrishnaInstitute for Infection and Immunity, St George's University of London, London, UK.
Youyou TuArtemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address: yytu@icmm.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ArtemisininsMalaria, FalciparumCambodiaDrug ResistanceHumansPiperazinesProspective StudiesQuinolinesThailandTreatment FailureVietnamArtemisininsartenimolpiperaquinePiperazinesQuinolines

Identifiers

PMID31657775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.